Literature
Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., … & Kirkland, J. L. (2019). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine.
Category: biotech/medical – Page 2,545
Industrial chemicals pass from mother to fetus throughout pregnancy
In a study published in Environment International researchers at Karolinska Institutet in Sweden show how PFAS industrial chemicals, which are used in many consumer products, pass through the placenta throughout pregnancy to accumulate in fetal tissue. Further research is now needed to ascertain the effect that highly persistent PFAS chemicals have on the fetus.
The PFAS (perfluoroalkyl substances) group comprises thousands of human-made chemicals, which, thanks to their water- and grease-resistant properties, are used in everything from frying pans and food packaging to clothes, cleaning agents and firefighting foams.
“We’ve focused on six of these PFAS substances and found that all appear to the same extent in fetal tissue as in the placenta,” says Richelle Duque Björvang, doctoral student at the Department of Clinical Science, Intervention and Technology, Karolinska Institutet. “So when the baby is born, it already has a build-up of these chemicals in the lungs, liver, brain, and elsewhere in the body.”
15-minute Workouts May Reverse Type 2 Diabetes in Just Six Weeks
F ifteen-minute workouts could reverse diabetes in just six weeks, new research suggests. A trial of overweight men found that short, intense resistance training sessions three times a week significantly boosted their ability to manage insulin.
Previous research has indicated that 45-minute workouts could have this effect, but the new study has been greeted with particular excitement as experts believe type 2 diabetes patients will be more likely to commit to shorter sessions.
It is estimated that by 2025 there will be five million people with a diabetes diagnosis in the UK, 90 per cent of whom will have type 2, which is related to lifestyle.
Scientists relieved but wary as US shutdown ends
The shutdown dragged on two weeks longer than any other in US history, and its effects on science have been profound. It has interrupted studies of everything from California’s coastal fisheries to clinical trials of experimental drugs, and key federal data sets have been pulled offline. Employees at many science agencies were forced to stay at home without pay for more than a month, and academic researchers have been deprived of key research funding.
Federal researchers head back to work after politicians approve deal to reopen government for three weeks. Federal researchers head back to work after politicians approve deal to re-open government for three weeks.
Drug compound could be next-generation treatment for aggressive form of leukemia
Researchers have been struggling for years to find a treatment for patients who have a recurrence of acute myeloid leukemia (AML), an aggressive blood cancer that is one of the most lethal cancers. About 19,520 news cases are diagnosed a year, and about 10,670 people a year die from it, according to the American Cancer Society.
Purdue University researchers are developing a series of drug compounds that have shown promise in treating such cases. About 30 percent of AML patients have a mutation caused by a kinase called FLT3, which makes the leukemia more aggressive. Inhibitors of FLT3, such as Radapt, approved last year by the U.S. Food and Drug Administration, have shown good initial response to treating leukemia. Gilteritinib, another FLT3 inhibitor, was recently approved toward the end of 2018. But AML patients on FLT3 inhibitor therapy often relapse because of secondary mutations in the FLT3 and existing treatments have not been fully successful in treating those cases.
Researchers on a team led by Herman O. Sintim, the Drug Discovery Professor of Chemistry in Purdue’s Department of Chemistry, say they have developed a series of compounds that work not only on AML with common FLT3 mutation, but also drug-resistant AML harboring problematic mutations, such as the gatekeeper F691L mutation, which some leukemia patients who relapse harbor.
Clinton Township, MI
We specialize in the cryo-preservation of humans and pets, DNA & tissue storage as well as cryonics outreach and public education.
UNITY Expands Human Senolytic Trial
UNITY Biotechnologies has recently announced an expansion of its first-stage human trial of UBX0101, a drug that has been shown to have senolytic properties in mice [1] and that the company hopes will be useful in treating painful osteoarthritis of the knee.
An expanded clinical trial
UNITY Biotechnologies, a $495 million biotech company in the process of creating senolytic medicines that target one of the aging processes, has just announced an expansion of its first-stage human trial of the first drug in its pipeline (UBX0101), which targets painful osteoarthritis of the knee.